Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth platforms. The strategy comes as rival Eli Lilly & Co. is working with telehealth firms to distribute lower-cost vials of its own obesity medication,

Deals with Hims & Hers, LifeMD and Ro following a court's dismissal of a lawsuit challenging the FDA's determination Wegovy is no longer in shortage.

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.